ArticleActa epileptologica2025
The efficacy and safety of vagus nerve stimulation in pediatric epilepsy in China: a multicenter cohort study.
Article in Acta epileptologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe field of epilepsy neural regulation represented by VNS is rapidly developing. Our aim was to investigate the safety and effectiveness of vagus nerve stimulation (VNS) as an adjunct therapy for pediatric epilepsy in a multi-center study across China.
methodsChildren with epilepsy undergoing VNS as supplementary treatment were consecutively enrolled in this study. Eligibility was limited to children aged 1-16 years with a confirmed epilepsy diagnosis, a stable antiseizure medication regimen, and a minimum of two seizures per 28-day cycle during the 8-week retrospective baseline.
resultsEighty-seven children (54 males; mean age 8.21 ± 3.88 years, range 0-16) were included, with seizures beginning at an average age of 3.03 ± 2.90 years. A ≥ 50% reduction in seizure frequency was observed in 23.7% at 6 weeks, 20.3% at 10 weeks, 22.6% at 18 weeks, and 18.6% at 26 weeks. Seizure freedom was achieved in 17.1%, 15.9%, 11.3%, and 16.3% of patients at the same intervals. Two subjects experienced adverse events, both of which were mild and transient.
conclusionsVNS demonstrated moderate efficacy and a favorable safety profile as an adjunct treatment in children with epilepsy. Further large-scale, long-term studies are recommended to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.